Search 

BCAL Diagnostics is a Sydney, Australia based blood diagnostics company with research facilities based in Kentucky, USA.

The BCAL lipid biomarker test is a universal blood test for the effective screening and monitoring of breast cancer.  The BCAL test is being developed to be safe, cost effective, accurate and available to all women regardless of age, race and geographic location.

BCAL Diagnostics is near completion of a 200-patient study. Initial results indicate the BCAL test has a greater than 90% sensitivity and specificity in the diagnosis of invasive ductal carcinoma which is 85% of all breast cancers. 

This will lead to a range of BCAL breast cancer blood tests that can be used across the full breast cancer disease management continuum. from pre-disposition to screening to long term monitoring.

BCAL Diagnostics is now seeking Series B capital of $5-$10M USD to support its global commercialisation activities.

Bionic Vision Technologies is the commercial entity which holds license to the patents around technology developed by Bionic Vision Australia.

Bionic Vision Australia brings together Australia’s leading experts in medical bionics to develop a bionic eye to restore vision to people with retinitis pigmentosa and age-related macular degeneration.  A prototype device has been successfully implanted into three patients for two years demonstrating outstanding safety and efficacy. 

Our capabilities which  differentiate us from competitors include:

1. Novel surgical techniques providing greater safety and stability od wide view devices

2. World leading, pioneering vision processing software

3. Unique arrangement and stimulation strategies of the electrodes

4. Unique diamond electrode encapsulation for the high acuity device

5. World leading psychophysics laboratory for assessing functionality of the devices

6. Unprecedented expertise and proven track record in preclinical studies

Our development portfolio consists of  wide view devices which aim to increase mobility and independence of patients and a high acuity device which will allow patients the ability to read large letters and recognise faces

BioScience Managers is a venture capital life science investment firm headquartered in Melbourne, Australia. The group makes equity investments from $3M-5M and anticipates about 6 new investments this year. BioScience Managers invests globally. 

BioScience Managers will invest in companies across the life science space, including therapeutics, diagnostics and medical technology. The group does not invest in service providers. BioScience Managers considers all subsectors and indications, including orphan indications. The group will consider technology either in or prepared for human clinical trials and is open to all classes of devices. BioScience Managers seeks investments in novel technology and is not looking to gain share of an existing market. 

We are an Australian Biotechnology Company nearing completion on five year R&D programme into new, novel compounds from natural rare Australian extracts for both the prophylactic and treatment of giardiasis.

Current R&D programmes in both Australia and Boston, MA.

World’s first alternative natural treatment to antibiotic strength drugs of choice against bacteria and protozoa for animals envisages enormous market potential, including human, organic, veterinary and husbandry sectors   

Fast kill rate ‘within 5 minutes’  

Non-Toxic and safe for human and animal consumption.

No antibiotic resistance problems that plague current treatment modalities [due to multiple compounds]

Kills all the life cycle – Pluripotent and treats both the disease and the pathogenesis of the disease in multiple ways

MOA established and known [several]